Axsome has successfully delayed generic competition for its narcolepsy drug Sunosi until 2040.
Axsome Therapeutics has successfully delayed generic competition for its narcolepsy drug Sunosi until 2040.
The company announced on Wednesday that it …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Pooled phase 3 trials show reduced OSA severity with oral drug over 26 weeks
ASCO: Sac-TMT’s massive phase 3 program has a jarring gap. Does Merck plan to close it?
New Eucalyptus owner says Australia will have to wait on peptide push
Shionogi's COVID antiviral Xocova passes muster with FDA as post-exposure preventative
Deaths of Despair Drop; FDA Rejects ADHD Drug; Rafael Nadal's Anxiety Battle
Vinay Prasad's acting replacement, remembering genomics pioneer J. Craig Venter, and more biotech news from The Readout
ORLANDO — Among adults with mild to severe obstructive sleep apnea, those receiving AD109, an oral combination drug, vs. placebo…
Journavx revived an area of development long considered a graveyard. Can any other pain drugs keep investor excitement going?
Biogen said signals sugget the treatment decreases levels of tau and slows cognitive decline, particularly at the lowest dose.
Alzheimer's drug rollout letdown, a China-based heart drug startup, and more biotech news from The Readout
Biogen reported heavily anticipated Alzheimer’s data, saying its tau-targeting drug BIIB080 missed its primary endpoint in a…
